Rilpivirine
Class
Antiretroviral agents
Subclass
Non-nucleoside reverse-transcriptase inhibitors
Substance name
Rilpivirine hydrochloride
Brand names
Edurant®
Common formulations
Film-coated tablet
Contained in
Dolutegravir / rilpivirine (Juluca®)
Emtricitabine / rilpivirine / tenofovir alafenamide (Odefsey®)
Dosage and administration
Adults patients
HIV-1 infection • Treatment-naïve, HIV-1 RNA ≤ 100,000 copies/mL
HIV-1 infection • Treatment-experienced, HIV-1 RNA < 50 copies/mL
Indications for use
Labeled indications
Adults
Safety risks
Contraindications
Hypersensitivity to rilpivirine or its components
Concomitant use of CYP3A inducers
Warnings and precautions
Immune reconstitution inflammatory syndrome
Increased liver enzymes
Prolonged QT interval, depression, DRESS syndrome
Specific populations
Renal impairment
eGFR ≥ 30 mL/min/1.73 m²
eGFR < 30 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Unexplained abnormality in LFTs
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B1
Breastfeeding
Strongly consider avoiding breastfeeding in HIV-positive mothers who have access to formula feeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource